ArticleFrontiers in immunology2021

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Nicole Kashani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.